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1. Introduction  
Cystic fibrosis (CF) is a common autosomal recessive genetic condition affecting white 
population with an approximate incidence of 1 per 2500 live births (Davis et al., 1996), 
nearly 30,000 people in the USA (Olivier et al., 2003). Patients with this life-shortening 
disease have abnormally thickened secretions that facilitate chronic infection of the airways, 
bronchiectasis and early death. The respiratory pathogens most frequently isolated in these 
patients are Staphylococcus aureus and Pseudomonas aeruginosa. 
As the survival of this group of patients has been improved by better nutrition, intensive 
therapy to clear airway secretions and more aggressive use of antibiotics (FitzSimmons, 
1993, Ramsey, 1996), new pathogens such as Stenotrophomonas maltophilia, Burkholderia 
cepacia, Alkaligenes xylosoxidans, Nocardia spp., fungi and non tuberculous mycobacteria 
(NTM) are evolving (Burns et al., 1998; Burns & Saiman, 1999; Olivier et al., 1996) 
NTM have increasingly been reported in the world as pulmonary pathogens not only in 
immunosuppressed but also in non immunocompromised persons, mainly in patients with 
lung disease (bronchiectasis, hypersensitivity, pneumonitis, chest wall disorders, previous 
mycobacteriosis and CF) (Huang et al., 1999; Prince et al., 1989; Hjelte et al., 1990; Fauroux et 
al., 1997) 
Two important issues to consider are: 1) the clinical significance of isolation of a NTM 
(contamination, colonization or disease) (Hayes, 2005); and 2) bacterial overgrowth, 
especially with P. aeruginosa, leading to difficulty in the isolation of the mycobacterium from 
sputum samples.  
NTM produce insidious infections that require several months of combined antibiotic 
therapy, difficult eradication and frequent relapses with progressive lung function 
deterioration (Esther et al., 2010). They represent an important social and health problem 
(Olivier et al., 2003), with not well defined and unsolved aspects, such as mode of infection, 
pathogenic role, standardized treatment or prophylaxis.  
In this chapter we will review the main epidemiological, clinical, diagnostic, therapeutic and 
prophylactic aspects of NTM infections in CF patients. 
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2. Epidemiology and pathogenesis 
2.1 General aspects  
The term NTM refers to Mycobacterium spp. different to M. tuberculosis complex and M. leprae. 
These microorganisms are widely distributed in the environment (water, soil, dust, animals 
and food). Almost all NTM are less virulent and contagious than M. tuberculosis (Runyon, 
1959; Brown-Elliot et al., 2002). There are more than 100 described species, of which only 15-
20 produce infections in humans.  
NTM are resistant to chlorination and ozonation (Prim et al., 2004) and to multiple 
antiseptics and antibiotics. They are opportunistic microorganisms capable of causing 
disease in a different range of locations (skin and soft tissues, lymph nodes and lung) as well 
as disseminated diseases.  
The extent and severity of infection depends on the anatomic and immune integrity of the 
host. These bacteria can adhere to biomedical materials (catheters, prosthesis, filters or 
membranes of inhalation systems) forming a biofilm that may complicate the 
pharmacological treatment of such infections (Williams et al., 2009).  
Infection by NTM was first reported in a patient with CF in 1980 (Boxerbaum, 1980). Few 
infections were described before 1990, but in the last 20 years, NTM have emerged as new 
pathogens in CF (Griffith, 2003; Olivier et al., 1996). This increase may be due to several 
factors: greater survival of patients with CF, increasing their environmental exposure; more 
aggressive therapies, which facilitate susceptibility to infection; improved microbiological 
diagnostic methods; and better interaction between clinicians and microbiologists. In 1997, 
the American Thoracic Society (ATS) published a Consensus Statement that identified CF as 
a risk factor for NTM pulmonary disease in HIV-seronegative patients and provided 
recommendations for laboratory and clinical diagnosis of NTM infection (Official  Statement 
ATS, 1997).  
In summary, NTM are common in patients with CF but neither person to person nor 
nosocomial acquisition explain their high prevalence. Clinical significance of NTM is 
incompletely defined but patients with these organisms should be monitored with repeated 
sample cultures (Olivier et al., 2003).  
2.2 Pathogenesis  
Patients with CF have abnormally viscous and thickened airway and gastrointestinal 
secretions as a result of a defect or decrease in the transmembrane conductance regulator 
protein or gene product which regulates chloride and liquid secretions across epithelial 
surfaces and resorption of sodium and liquid. These thick respiratory secretions occlude the 
airways and ductal lumens leading to recurrent pulmonary infections, pancreatic 
insufficiency and intestinal obstruction (Welsh, 1990). 
NTM, which enter mainly through the respiratory tract, are phagocytosed by macrophages 
and survive and reproduce within patients until symptomatic infection occurs.  The disease 
manifestations depend on the immune cellular response and the possible granulome 
formation; hence, its difficult eradication and its tendency to persistence or recurrence 
(Morales et al., 2011). 
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2.3 Frequency and distribution 
Prevalence rates of NTM infections in patients with CF are variable, due mainly to the few 
multicenter studies (Olivier et al., 2003; Roux et al., 2009; Mussaffi, et al., 2005; Levy et al., 
2008) and their diversity in the methodology used, since some refer to patients who had at 
least one positive culture and others to those who met disease criteria following the ATS 
recommendations from 1997 (Official  Statement ATS, 1997) or 2007 (Griffith et al., 2007), 
obtaining fewer cases. 
Infection data vary between 2 and 30%, with an average of 13 to 15%. These differences are 
due to the number of cases reported in each study - the most numerous being Olivier et al, 
1186 and Roux et al, 1582-, the geographical location - with differences between continents 
(America greater reports) and within countries (the highest prevalence values were those 
reported for coastal states) - and the age of the patients included. In general, more isolates 
may be found in teenagers (10-20%) and young adults with CF (American Academy of 
Paediatrics, 2006).  
Regarding age, both multicenter studies and general observations, suggest that NTM 
infections occur as a complication in adolescents and young adults (10 to 25 years old) 
although with small differences between mycobacteria, since the rapidly growing can be 
acquired at almost any age and M. avium complex (MAC) in older patients (Roux et al., 2009). 
Some do not find significant differences among sex (Olivier et al., 2003), while as others 
describe more cases in women than men (Roux et al., 2009). 
2.4 Isolated NTM 
In relation to the isolated species of NTM, most authors agree that both, MAC and the 
rapidly growing mycobacteria (RGM), are the most frequent, accounting around 80% (Roux 
et al., 2009). Infection is usually caused by a single species and exceptionally by a mixture of 
two mycobacteria. 
MAC is composed of a group of slow, fastidiously growing mycobacteria that includes M. 
avium, M. intracellulare and unnamed genetically related species. It ranks first in North 
America with 72% of the isolates, mainly M. avium (Olivier et al., 2003) but is second and 
third in frequency in other series. M. abscessus, a member of the RGM (culture growth in less 
than 7 days) seems to prevail in Western Europe (Roux et al., 2009; Jönsson et al., 2007; 
Sermet-Gaudelus et al., 2003) and Israel (Levy et al., 2008), where M. simiae is also frequent. 
(Figure 1). 
M. abscessus may be confused due to its different classification in time, since it was first 
included within M. chelonae group, then as a different species by itself, and more recently as 
part of the M. abscessus complex (MABSC), together with M. massiliense (Adékambi et al., 
2004) and M. bolletii (Adékambi et al., 2006). 
The prevalence of these two groups - MAC and MABSC - varies with age. MABSC may 
appear at any age, but most frequently in teenagers age 11 to 15 years old, while as MAC is 
more common in young adults aged 20 to 25 (Pierre-Audigier et al., 2005; Rodman et al., 
2005). In all series, there is a minority group of varied mycobacteria named “others”, which 
includes M. gordonae (possible contaminant), M. fortuitum, M. kansasii, M. simiae, M. 
peregrinum, M. malmoense, all of them infrequent and poorly representative. 
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Fig. 1. Frequency of NTM species isolated in CF patients according to several studies 
(Olivier et al., 2003; Roux et al., 2009; Mussaffi et al., 2005; Levy et al., 2008).  
2.5 Transmission  
Given the ubiquitous nature of NTM, the port of entry for infection may be diverse: 
cutaneous, oropharyngeal mucosa, digestive or respiratory. NTM are frequently present in 
tap water and shower heads, where they remain viable in aerosols (Parker et al., 1983). 
Some, such as MAC, are resistant to chlorine and ozone, as already mentioned. Most 
infections remain near the port of entry but may also disseminate to other organs if the 
patient is immunocompromised. There is no evidence of person-to-person transmission of 
NTM infection. Therefore, no patient isolation but only universal precautions are necessary. 
Infections usually present as single cases, but outbreaks have also been reported, some of 
them by molecular techniques, secondary to a common focus neither identified nor 
corrected (Wallace et al., 1998; Kim et al., 2007; Viana-Niero et al, 2008).  
2.6 Risk factors 
In the last ten years, several authors have sought the relationship between NTM infection 
and different aspects of the patients, the disease or the microorganisms involved, describing 
some predisposing or risk factors (Table 1). (Olivier et al., 2003; Roux et al., 2009; Mussafi et 
al., 2005; Levy et al., 2008). 
 
Age Sweat chloride P. aeruginosa 
Race Insulin-requiring diabetes S. aureus 
Sex Pancreatic enzymes use Aspergillus spp. 
BMI Steroids  Sputums cultured 
Place of residence  Severe genotypes FEV1 
BMI, body mass index; FEV1, forced espiratory volume in the 1st second. 
Table 1. Predictors of NTM infection in CF patients 
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Olivier et al, compared CF patients with and without positive culture for NTM. The culture-
positive patients were significantly older (26 versus 22, p<0,001), had higher FEV1 (60% 
versus 54%), higher frequency of S. aureus (43% versus 31%) and lower frequency of P. 
aeruginosa co-infection (71% versus 82%). Another related factor was the body mass index 
(BMI). There were no significant differences between M. abscessus and MAC. When several 
risk factors are present (for example, age, FEV1 and S. aureus co-infection) the probability of 
having NTM is 50-fold higher. 
Roux et al, found nuances in age between the two groups of mycobacteria, as previously 
mentioned, suggesting that this difference may be due to the different degree of virulence of 
these mycobacteria. Women were more frequently affected, a fact not previously referenced. 
Little is known about the clinical significance and the risk factors of the new species of RGM, 
apart from their tendency to produce cutaneous lesions. A recent study has also found 
clinical differences between M. maxiliense and M. abscessus infection (Zelazny et al., 2009).  
Levy et al, found that the presence of Aspergillus spp. in sputum and the number of the 
sputum specimens processed for mycobacteria were the most significant predictors for 
isolation of NTM.  
Mussafi et al, have found a relationship between pulmonary M. abscessus disease and 
allergic bronchopulmonary aspergillosis and corticosteroid therapy. Eradication of infection 
was more difficult in these circumstances.  
In addition to the risk factors analyzed, we must not forget that, back in 1997, the ATS 
published a consensus document identifying CF as a risk factor itself for NTM infection, 
providing extensive information about it. 
3. Clinical manifestations and radiology  
Clinical manifestations, together with radiological findings and the microbiological cultures 
that will be commented further on, constitute the three basic pillars for the diagnosis of 
NTM disease (Table 2) (Griffith et al., 2007). 
 
CATEGORY REQUIREMENTS 
Clinical findings 
 
 
Radiological findings 
 
 
Bacteriological findings 
 
Pulmonary symptoms  
Exclusion of other diagnoses 
 
Chest X-ray: nodular or cavitary images; or 
HRCT: multifocal bronchiectasis with multiple small nodules. 
 
 
Sputum: 2 or more positive cultures or BAS or BAL: ≥ 1 
positive culture or lung biopsy: granulomatous inflammation 
or positive staining for AFB together with one or more 
positive cultures (biopsy, sputum, BAS; BAL) 
Table 2. ATS / IDSA criteria for the diagnosis of lung disease caused by NTM 
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Diagnosis requires: all the clinical criteria + 1 radiological criterion + 1 bacteriological 
criterion. ATS: American Thoracic Society; IDSA: Infectious Diseases Society of America; 
NTM: Non-tuberculous Mycobacteria; HRCT: high-resolution computerized tomography; 
BAS: bronchoalveolar secretions (aspirate); BAL: bronchoalveolar lavage; AFB: acid-alcohol 
resistant bacilli. 
Lung infections in general tend to have non specific symptoms (cough, dyspnea, weight 
loss, increased expectoration, sometimes hemoptysis) and chest radiographic findings that 
vary from innocuous or no findings, to infiltrates or nodules, sometimes cavitated, (Morales 
et al., 2007) with HRCT scanning chest abnormalities - nodules and/or multifocal 
bronchiectasis (Hayes, 2005).  
The chest radiography in NTM pulmonary disease caused by RGM is likely to show 
multilobular, patchy, reticulonodular or mixed interstitial and alveolar infiltrates with upper 
lobe predominance and cavitation in only 15% of cases (Griffith et al., 1993, Daley & Griffith, 
2002) (Figure 2).  
 
Fig. 2. Chest radiography of M. abscessus infection in CF patient. 
The most common radiographic changes in MAC infection are cavitary disease and 
fibronodular bronchiectasis (Goo & Im, 2002). Cavities are finer and surrounded by less 
parenchymal opacification than in the case of tuberculosis (TB) (Erasmus et al., 1999). 
Bronchiectasis appear preferentially in the middle lobe and lingula (Lynch et al., 1995). 
Pleural effusion is not common. In HRCT scanning, the presence of bronchiectasis and 
multiple small nodules are predictive of MAC lung disease (Maycher et al., 2000). 
Cutaneous manifestations may vary from small single nodes to ulcers, sometimes coincident 
with skin disruptions such as wounds, burns, surgical incisions, catheter implantation sites 
and so forth. These cutaneous lesions are very important in lung transplant recipients (LTx), 
since they can be the first sign of dissemination (Taylor & Palmer, 2006, Morales et al., 2007).  
In isolated cases and, especially, in immunossuppressed patients, including transplant 
recipients, infection may diseminate to other organs, like from skin to lungs, intestine or 
other sites.  
www.intechopen.com
 
Infection by Non Tuberculous Mycobacteria in Cystic Fibrosis 
 
213 
3.1 Clinical course and evolution 
Clinical course is similar to that of TB, with insidious and slow progression that requires 
combined treatment for various months. This is difficult to comply due to its adverse effects 
and interactions with other drugs. Initial clinical and microbiological response is usually 
good but, even after complete compliance, with apparently successful therapy, there is a 
tendency to persistance and relapse (Mussaffi et al., 2005). NTM affects pulmonary function 
and chronic lung infection in CF patients is the main cause of morbidity and mortality  
(Esther et al., 2010). There is no data of mortality directly associated to mycobaterial 
infection, since these patients usually suffer simultaneous infections by different 
microorganisms (Figure 3). 
 
Fig. 3. Modified Ziehl-Neelsen stain showing co-infection of Mycobacterium spp. with 
Aspergillus spp. in a CF patient. 
4. Microbiological diagnosis 
Samples that reach the laboratory are mainly of respiratory origin (sputum, pleural fluid or 
its biopsy specimen, BAL and lung biopsy specimen). They can also be from skin or other 
locations if infection is disseminated. 
With the staining methods - Ziehl-Neelsen or auramine fluorescence -, there are features on 
the AFB in terms of their number, shape, and grouping, that characterize the different NTM.  
Bacterial overgrowth, especially with P. aeruginosa, is problematic and leads to difficulties in 
isolating mycobacteria from respiratory secretions and sputum. Therefore, together with the 
classical decontamination process using 0.25% N-acetylcysteine and 1% NaOH, addition of 
5% oxalic acid is recommended (Whittier et al., S. 1997) 
Samples are cultured in solid (Löwenstein-Jenssen or other) and liquid media (radiometric 
BACTEC 460 and nonradiometric BACTEC 9050 and 960, Becton Dickinson, or other). Some 
NTM have specific requirements for culture, such as temperature (MAC 42ºC) and  time 
(RGM grow in less than 7 days, whereas others in 10-14 days). 
Colonies may be identified phenotypically in most cases (Kent & Kubica, 1983, Metchock et 
al., 1999) and be confirmed by molecular typing methods, using commercial RNA/DNA 
probes (AccuProbe, GenProbe, San Diego, Ca) (Cousins et al.,1996, Wallace et al., 1998) and 
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other techniques (Zhang et al., 1997). The different species included in the MABSC are 
distinguished by rpoB sequencing (AdéKambi et al., 2003). Molecular identification of the 
mycobacteria also helps in differentiating between relapse and reinfection, and in 
determining whether an outbreak is secondary to a common origin or not.  
Chromatography techniques (Butler & Guthertz, 2001) are less used, since they are more 
complex and less precise (Leite et al., 2005). Serologic diagnosis, such as determining the 
presence of IgG immunoglobulin against antigen A 60 (Oliver et al., 2001), has been 
discarded due to its low sensitivity and specificity (Pottumarthy et al., 2000). Tuberculin 
skin testing may be positive in patients infected with NTM, since M. tuberculosis shares 
antigens with various species, but generally the induration induced is less than 10 mm in 
diameter (Field & Cowie, 2006). Techniques based on lymphocyte interferon gamma (IFN-γ) 
production have been developed and can be useful in distinguishing between infection by 
M. tuberculosis, NTM, or BCG vaccination (Scholvink et al., 2004).  
There is controversy over the systematic use of susceptibility testing of NTM, since there is 
no clear correlation to the clinical therapeutic response. At least for clarithromycin in the 
case of MAC disease there are some recommendations (Wayne, 2000). RGM are intrinsically 
resistant to classic antituberculous drugs and have variable antimicrobial susceptibility 
profile. Clinically significant isolates should be tested against amikacin, cefoxitine, 
ciprofloxacin, clarithromycin, doxycycline, imipenem, trimethoprim/sulfamethoxazole and 
recently, linezolid (Woods, 2000). Synergy studies with two or more antibiotics can also be 
done. Methods used include dilution, diffussion (E-test) and automated techniques. 
5. Treatment and evolution  
5.1 General aspects  
No guidelines exist for the treatment of NTM pulmonary diseases in the CF population. 
Given the natural tendency of these bacteria to seek refuge in macrophages and to the fact 
that in vitro susceptibility tests do not show true antibiotic concentration, combined therapy 
may favour synergy and minimize the appearance of resistance. It is difficult to determine a 
treatment of choice since experience is limited and results are variable, and in vitro tests do 
not always correlate to in vivo response. Duration of treatment is also variable, depending on 
the NTM to be treated, the severity and extent of disease, and the clinical and immune status 
of the patient. In any case, treatment compliance is difficult since it is long lasting, antibiotics 
have adverse effects and interactions with other drugs, in particular with 
immunesuppressors in the case of transplant recipients. A close clinical and microbiological 
surveillance of the patients is necessary, to watch out for possible relapses, dissemination or 
risk of graft rejection in the case of transplantation (Morales et al, 2007; Morales et al., 2011). 
We will focus on the treatment of MAC and M. abscessus, the most frequent NTM in CF 
patients. Treatment of the less common mycobacteria requires individualized 
considerations, keeping as a basic principle the combination of two or three active drugs. 
5.2 Treatment of MAC 
Transmission of the mycobacteria included in the MAC is varied, but mainly through birds 
and water (Marras et al., 2005). Infection has been related to recreational hot-tubs and can 
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cause a hypersensitivity pneumonitis like syndrome in exposed patients (Embril et al., 1997; 
Rickman et al., 2002; Hanak et al., 2006).  
Mycobacteria included in the MAC are resistant to first-line antituberculous drugs –
rifampicin, isoniazid and streptomycin - except for ethambutol, and are usually susceptible 
to amikacin and macrolides, in particular clarithromycin. 
Initial treatment includes ethambutol, clarithromycin or azithromycin and a third drug 
according to susceptibility test results. Duration of treatment is from 6 to 9 months for small 
lesions and up to 12-24 months in case of dissemination. Combination of ethambutol, a 
macrolide and rifampicin has been used successfully due to their synergism and good 
tolerance (Field & Cowie, 2003). Some authors recommend maintenance of the macrolide 12 
more months once patients convert to negative, thus reducing the number of relapses (ATS, 
1997). The importance of macrolides relies on the intracellular penetrance of both, the 
antibiotic and the bacteria. First recommendations included clarithromycin (Field & Cowie, 
2003) and then azithromycin (Griffith et al., 2001), but always in combination and not in 
monotherapy as initial drugs. 
M. avium is the most common cause of immune reconstitution inflammatory syndrome 
caused by NTM (Field & Cowie, 2006). IFN-γ is a macrophage activator in response to 
mycobacteria. Patients with disseminated MAC infection, with relapses or poor prognosis, 
respond favorably to inhaled IFN-γ (Holland et al., 1994; Hallstrand et al., 2004).  
In exceptional cases, when infection is localized and with persistent lung affection, surgery 
has been applied. Post-operative morbidity and complications that include hemorrhages, 
bronchopleural fistula and empyema are possible.  
5.3 Treatment of M. abscessus and other RGM 
This group of mycobacteria is ubiquitous and can survive in adverse conditions. They can 
grow in any culture media used in bacteriology in less than 7 days, with the risk of not being 
evaluated or being considered as contaminants. Although it includes various species, the 
most relevant and virulent in CF patients is M. abscessus. This mycobacterium can cause skin 
infection, lung disease or even disseminate. Its treatment is difficult due to its 
multiresistance, not only to the classic, already mentioned antituberculous drugs, including 
ethambutol, but also to ampicillin, amoxicillin-clavulanate, cefoxitin, ciprofloxacin, 
erythromycin, sulfamethoxazole and tobramycin. It is universally susceptible to amikacin, 
and a recommended treatment is the combination of amikacin, clarithromycin and 
imipenem for 6 to 9 months (Yang et al., 2003). There can be initial improvement, but 
relapses are very frequent, in which case, therapy should be extended and/or a drug should 
be changed according to susceptibility testing. Other alternative therapeutic agents include 
the new oxazolidinone, linezolid, that is active against RGM (Wallace et al., 2001) with good 
therapeutic results (Morales et al, 2007). An open line includes the new quinolones 
gatifloxacin and moxifloxacin. 
In the presence of big lung abscesses, a very rare presentation, surgical drainage might be 
necessary and can potentially lead to extrapulmonary seeding of the infecting mycobacteria 
and be an added risk if lung transplantation is needed. 
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Recommended suppressive therapy includes oral clarithromycin and aerosolized amikacin 
(Cullen et al., 2000; Colin AA, 2000). Monotherapy must always be avoided, since the most 
common cause of macrolide resistance is the use of clarithromycin as single drug in patients 
with CF and disseminated cutaneous infection (Wallace et al., 1996). 
6. Prophylaxis  
Given the extensive and varied presence of NTM in the environment and their variable 
susceptibility to antibiotics, the inevitable environmental exposure of CF patients and the 
lack of person-to-person transmission, primary chemoprophylaxis is not indicated. The only 
situation in which clarithromycin or azithromycin would be recommended is in HIV 
positive patients over 6 years of age and with a CD4 count of less than 50/L, with risk of 
MAC infection (American Academy of Pediatrics, 2006).  
Clinical and radiological monitoring is important, including intensive and selective search 
for NTM, in pulmonary samples from suspected foci, especially in young adults with 
impaired lung disease, Aspergillus spp. and steroid treatment. 
On the other hand, it is important to take into consideration the life style of the patient, with 
a watchful attitude towards surrounding environment, being aware that it constitutes an 
unavoidable but reducible risk. Recently, a practical and excellent guideline in this regard 
has been published (Avery et al., 2009) 
7. Peri-transplant considerations  
7.1 Pre-transplant 
As has been discussed, NTM infections must be kept in mind in the differential diagnosis of 
any lung disease in CF patients, especially when approaching an indication of LTx. 
Identification and in vitro susceptibility of the mycobacteria are required to ensure proper 
treatment and to achieve complete recovery before transplantation. 
In particular, so difficult is the treatment of M. abscessus infection, that it has been 
considered a strong relative contraindication to LTx (Orens et al., 2006). Recently, Gilljama et 
al., reported their experience in three double LTx CF patients with ongoing therapy, and a 
fourth with recent treatment for M. abscessus lung infection. The first three developed skin 
infection and abscesses. Recovery was finally accomplished and pulmonary function was re-
established after a prolonged 7 years long follow-up. With this, they conclude that LTx is 
feasible but may involve severe complications.  
7.2 Post-Transplant 
Infection and graft rejection in organ recipients are the two main causes of morbidity and 
mortality. Transplant may lead to the reactivation of a previously undetected infection, to its 
dissemination or to its initial onset. NTM have emerged as important pathogens in these 
patients, especially in LTx, causing pulmonary and extrapulmonary infections (Malouf & 
Glanville, 1999). These bacteria have also been identified as a potential cause of graft 
dysfunction and mortality by themselves or together with other opportunistic pathogens, 
which is a very common situation. In particular, infection by M. abscessus may be fatal 
www.intechopen.com
 
Infection by Non Tuberculous Mycobacteria in Cystic Fibrosis 
 
217 
(Sanguinetti et al., 2001; Fairhurst et al., 2002) or resolve even when disseminated (Morales 
et al, 2007) 
7.3 Donor 
Even though we have not found any documented case of NTM infection in the organ donor, 
mycobacteriosis would be hypothetically a relative contraindication for transplantation. 
Systematic search of NTM in the bronchoaspirate of donors must be done to introduce 
treatment as soon as possible.  
8. Final considerations  
 Life expectancy and quality of life have improved in CF patients and their treatments 
have turned/become more aggressive. 
 NTM cause frequent pulmonary infection especially related to advancing age and lung 
function deterioration. M. abscessus and MAC are the most frequently isolated NTM.   
 Early clinical suspicion is important. The routine or selective mycobacterial search 
according to known risk factors is an important decision. No comparative studies 
indicate which option is the most effective. 
 NTM must be decontaminated, cultured and typified thoroughly, since species 
identification is crucial for treatment and other clinical considerations.  
 When a NTM is isolated from a sputum sample, both clinician and microbiologist will 
determine whether it should be considered a contaminant, colonization or infective 
agent, with the consequent attitude.  
 It is important to perform correctly the in vitro susceptibility tests and to try new 
antibiotics against NTM. 
 Ensure treatment compliance, since it will prevent the emergence of antibiotic 
resistance, infection relapse and poor outcome. 
 Since there are no primary chemoprophylaxis recommendations, patients should be 
oriented to a healthy life style. 
 If the moment for the lung transplant arrives, all the previously mentioned 
considerations should be taken very seriously, since the probability for infection and 
dissemination are greater due to the immunosuppressive therapy. 
 These processes pose significant social and health burdens (school absenteeism, work 
and family limitations, doctor visits, hospitalization, diagnostic testing and treatment) 
with the resulting economic impact. 
Future should rely on early suspicion and adequate search for NTM, the use of modern 
microbiological techniques applied directly on the sample, safer and more active 
antibiotics, research of mycobacterial virulence factors and the determinants for 
persistence of infection.  
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